Robert J. Soiffer

Oncology

450 Brookline Ave
Boston, MA 02215

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 280 publications

Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.

Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 25, 2026

Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.

Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 30, 2026

Venetoclax-Augmented RIC Allogeneic HCT With PTCy-Based GVHD Prophylaxis and Venetoclax/Azacitidine Maintenance for Poor Risk MDS and AML.

Venetoclax-Augmented RIC Allogeneic HCT With PTCy-Based GVHD Prophylaxis and Venetoclax/Azacitidine Maintenance for Poor Risk MDS and AML.

Journal: Transplantation and cellular therapy

Published: April 28, 2026

Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML.

Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML.

Journal: Blood advances

Published: March 25, 2026

Graft manipulation and GVHD: what goes around comes around.

Graft manipulation and GVHD: what goes around comes around.

Journal: Blood

Published: March 12, 2026

Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?

Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 21, 2026

Early persistence of recipient stem-cells and T-cell dysregulation are associated with relapse after transplant in AML/MDS.

Early persistence of recipient stem-cells and T-cell dysregulation are associated with relapse after transplant in AML/MDS.

Journal: bioRxiv : the preprint server for biology

Published: November 26, 2025

Impact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CI.

Impact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CI.

Journal: Transplantation and cellular therapy

Published: November 22, 2025

eGFR Discordance and Its Association with Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation and Adoptive T-Cell Therapies.

eGFR Discordance and Its Association with Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation and Adoptive T-Cell Therapies.

Journal: Journal of the American Society of Nephrology : JASN

Published: November 20, 2025

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML.

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML.

Journal: Blood advances

Published: October 01, 2025

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AML.

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AML.

Journal: Blood advances

Published: October 01, 2025

Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation.

Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation.

Journal: Bone marrow transplantation

Published: September 19, 2025

Showing 1-12 of 280

Last Updated: 09/26/2026